BVT Call 350 AMGN 21.06.2024/ DE000VM78BU8 /
2024-05-09 8:38:33 AM | Chg.+0.013 | Bid7:57:34 PM | Ask7:57:34 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.032EUR | +68.42% | 0.060 Bid Size: 52,000 |
0.075 Ask Size: 52,000 |
Amgen Inc | 350.00 USD | 2024-06-21 | Call |
GlobeNewswire
7:00 AM
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-02
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Canc...
GlobeNewswire
05-01
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Su...
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
04-24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...